Low Beclin-1 expression predicts improved overall survival in patients treated with immunomodulatory drugs for multiple myeloma and identifies autophagy inhibition as a promising potentially druggable new therapeutic target: an analysis from The Austrian

Abstract:

:Beclin-1 is a key regulator of autophagy and has been suggested to be involved in the development of drug resistance in multiple myeloma (MM). We analyzed the expression of Beclin-1 in a retrospective cohort of 70 MMs. Beclin-1 expression did not influence overall survival (OS) and progression-free survival (PFS) in patients with therapy-naïve MM. In patients treated with immunomodulatory drugs (IMiDs) lack of or low Beclin-1 expression resulted in a significantly improved OS and PFS compared to those treated with bortezomib or nonnovel agents. Beclin-1 expression was more frequently detected in relapsed MM than in therapy-naïve MM probably being a hallmark of tumor progression and therapy resistance. If validated prospectively, Beclin-1 expression might identify patients prone to profit above average from IMiDs and enable a more rational allocation of antimyeloma therapies. Furthermore, the inhibition of autophagy could be a new promising target to improve response to treatment in the relapsed/refractory setting.

journal_name

Leuk Lymphoma

journal_title

Leukemia & lymphoma

authors

Willenbacher W,Thangavadivel S,Greil R,Willenbacher E,Weger R,Manzl C,Jöhrer K,Brunner A

doi

10.3109/10428194.2016.1144880

subject

Has Abstract

pub_date

2016-10-01 00:00:00

pages

2330-41

issue

10

eissn

1042-8194

issn

1029-2403

journal_volume

57

pub_type

杂志文章
  • Resistance to apoptosis induced by serum depletion and all-trans retinoic acid in drug-resistant leukemic cell lines.

    abstract::The relation between resistance to anticancer drugs and resistance to apoptosis has been investigated in the human leukemic cell line(KY-821) and its drug-resistant sublines. Under serum depletion conditions, drug-resistant cell lines showed apoptotic resistance when compared with the parental cell line. Drug resistan...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199709051787

    authors: Kakihara T,Fukuda T,Kamishima T,Naito M,Tanaka A,Uchiyama M,Kishi K

    更新日期:1997-07-01 00:00:00

  • Genistein inhibited proliferation and induced apoptosis in acute lymphoblastic leukemia, lymphoma and multiple myeloma cells in vitro.

    abstract::Genistein is one of the major isoflavones in soy products. It has been reported that genistein has apoptotic effects on certain hematological malignancies. However, so far there have been no completely comparative studies of the effect of genistein on malignant hematological diseases, especially multiple myeloma. We i...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2011.598251

    authors: Li W,Frame LT,Hoo KA,Li Y,D'Cunha N,Cobos E

    更新日期:2011-12-01 00:00:00

  • A controlled trial of tranexamic acid therapy for the reduction of bleeding during treatment of acute myeloid leukemia.

    abstract::In order to determine the efficacy of the antifibrinolytic agent tranexamic acid (TA) in reducing bleeding and platelet transfusions during the treatment of acute myeloid leukemia (AML), we conducted a randomized placebo-controlled double-blind study. Patients with AML undergoing induction or postremission consolidati...

    journal_title:Leukemia & lymphoma

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.3109/10428199509059668

    authors: Shpilberg O,Blumenthal R,Sofer O,Katz Y,Chetrit A,Ramot B,Eldor A,Ben-Bassat I

    更新日期:1995-09-01 00:00:00

  • Richter's syndrome in the brain first manifested as an ischaemic stroke.

    abstract::Isolated central nervous system involvement in Richter's syndrome (RS) is extremely rare and only 6 such cases have been described, so far. We report a 60-year-old woman with B-cell chronic lymphocytic leukemia (B-CLL) heavily pretreated with cladribine based regimens and rituximab in whom RS in the brain was first ma...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190310001638823

    authors: Robak T,Góra-Tybor J,Tybor K,Jamroziak K,Robak P,Kordek R,Rieske P,Majos A,Urbańska-Ryś H

    更新日期:2004-06-01 00:00:00

  • Apoptosis in chronic myelogenous leukemia: studies of stage-specific differences.

    abstract::In this study we compared rates of apoptosis, survival and metabolic activity from CML peripheral blood neutrophils with peripheral blood and bone marrow neutrophils from healthy volunteer donors and studied the influence of the disease stage and of cytokines including G-CSF, GM-CSF and IL-1beta on these parameters. Q...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199709042502

    authors: Gisslinger H,Kurzrock R,Wetzler M,Tucker S,Kantarjian H,Robertson B,Talpaz M

    更新日期:1997-03-01 00:00:00

  • A critical reappraisal of the WHO classification of the chronic myeloproliferative disorders.

    abstract::Following the introduction of the WHO classification of chronic myeloproliferative disorders (MPDs), after approximately 5 years, a critical reappraisal appears to be warranted. Retrospective clinico-pathological evaluations conducted in the meantime, as well as the detection of new biomarkers, may aid in testing the ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.1080/10428190500331329

    authors: Thiele J,Kvasnicka HM

    更新日期:2006-03-01 00:00:00

  • The serum levels of eosinophil cationic protein (ECP) are related to the infiltration of eosinophils in the tumours of patients with Hodgkin's disease.

    abstract::We have previously described a relation between abundance of eosinophilic granulocytes in Hodgkin's disease (HD) tumours and poor prognosis. In order to further explore the importance of the eosinophilic infiltration, we immunohistochemically examined the presence of eosinophils, using the monoclonal antibodies EG 1 a...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428190109064602

    authors: Molin D,Glimelius B,Sundström C,Venge P,Enblad G

    更新日期:2001-07-01 00:00:00

  • The impact of cell-of-origin, MYC/Bcl-2 dual expression and MYC rearrangement on disease relapse among early stage diffuse large B-cell lymphoma patients treated with combined modality therapy.

    abstract::We addressed the prognostic impact of cell-of-origin (COO), MYC and Bcl-2 overexpression as well as isolated MYC rearrangement among 111 patients with limited stage diffuse large B-cell lymphoma (DLBCL) treated with consolidative radiation therapy (RT) after a metabolic complete response to immunochemotherapy. With a ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2020.1869965

    authors: Augustyn A,Medeiros LJ,Ludmir EB,Gunther J,Fang P,Li S,Ok CY,Bankston ME,Verma V,Pasalic D,Ahmed S,Nastoupil LJ,Westin JR,Strati P,Neelapu SS,Nair R,Steiner RE,Iyer SP,Rodriguez A,Fayad LE,Flowers CR,Dabaja BS,

    更新日期:2021-01-22 00:00:00

  • The impact of time from diagnosis to treatment in diffuse large B-cell lymphoma.

    abstract::Diffuse large B-cell lymphoma (DLBCL) is a high-grade lymphoma that requires treatment. We retrospectively analyzed the impact of time from diagnosis-to-treatment (TDT) on progression-free survival (PFS) and overall survival (OS) in 581 R-CHOP-treated patients. TDT was defined as the interval between diagnostic biopsy...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2017.1422863

    authors: Phipps C,Lee YS,Ying H,Nagarajan C,Grigoropoulos N,Chen Y,Tang T,Goh AZ,Ghosh A,Ng HJ,Gopalakrishnan S,Loh Y,Lim ST,Hwang W,Tan D,Goh YT

    更新日期:2018-10-01 00:00:00

  • Clinical and pathological differences between human immunodeficiency virus-positive and human immunodeficiency virus-negative patients with plasmablastic lymphoma.

    abstract::Plasmablastic lymphoma (PBL) is a distinct variant of diffuse large B-cell lymphoma initially described in HIV-positive patients. Several studies have reported the occurrence of PBL in HIV-negative patients, but comparative data are lacking. The goal of this study was to compare the characteristics of HIV-positive and...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2010.516040

    authors: Castillo JJ,Winer ES,Stachurski D,Perez K,Jabbour M,Milani C,Colvin G,Butera JN

    更新日期:2010-11-01 00:00:00

  • Augmented myeloablative conditioning with thiotepa in acute myeloid leukemia - improved outcomes with similar toxicity.

    abstract::Myeloablative doses of busulfan (Bu) with fludarabine (Flu) have reduced toxicity, however, limited by an increased relapse rate. We aimed to improve outcome of Flu-Bu regimen by augmentation with thiotepa (TT) (10 mg/kg). Eighty-nine patients with AML, 44 patients conditioned with Flu-Bu (group 1), and 45 patients au...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2018.1510495

    authors: Sheth V,Nachmias B,Grisariu S,Avni B,Or R,Shapira M

    更新日期:2019-03-01 00:00:00

  • Acute myeloid leukemia in the elderly: etoposide when anthracyclins are contraindicated.

    abstract::We investigated whether etoposide might be a suitable alternative to anthracyclins for the treatment of elderly patients with acute myeloid leukemia (AML) in whom anthracyclins are contraindicated. In total, 88 patients over 60 years old were treated in our department between 1988 and 2000 for de novo or secondary AML...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190400013134

    authors: Chaoui D,Peffault De Latour R,Legrand O,Marie JP

    更新日期:2005-03-01 00:00:00

  • Ubiquitin-proteasome system and increased sensitivity of B-CLL lymphocytes to apoptotic death activation.

    abstract::The ubiquitin-proteasome-dependent proteolytic system has been reported to regulate apoptotic cell death in many experimental cell models. We recently found that B-CLL (chronic lymphocytic leukemia) lymphocytes are hypersensitive to apoptotic death activation through specific inhibition of proteasome function by lacta...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428190009059268

    authors: Masdehors P,Merle-Béral H,Magdelénat H,Delic J

    更新日期:2000-08-01 00:00:00

  • Exposure of chronic myelogenous leukemia cells to imatinib results in the post-transcriptional induction of manganese superoxide dismutase.

    abstract::The treatment of chronic myelogenous leukemia (CML) with specific tyrosine kinase inhibitors typically results in clinical success, although therapeutic failure frequently occurs. In order to investigate the biological consequences of treating CML cells with such drugs, we previously reported that the antioxidant sele...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2014.944521

    authors: Reinke EN,Bera S,Diamond AM

    更新日期:2015-04-01 00:00:00

  • Activation-induced cytidine deaminase mRNA levels in chronic lymphocytic leukemia.

    abstract::The Rai and Binet staging systems, which are used as standard methods for evaluating the prognosis of chronic lymphocytic leukemia (CLL), have some restrictions in identifying patients with early-stage CLL who will progress rapidly. To solve this defect, other prognostic parameters have become important in recent year...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2010.531410

    authors: Hancer VS,Kose M,Diz-Kucukkaya R,Yavuz AS,Aktan M

    更新日期:2011-01-01 00:00:00

  • Arsenic trioxide in front-line therapy of acute promyelocytic leukemia (C9710): prognostic significance of FLT3 mutations and complex karyotype.

    abstract::The addition of arsenic trioxide (ATO) to frontline therapy of acute promyelocytic leukemia (APL) has been shown to result in significant improvements in disease-free survival (DFS). FLT3 mutations are frequently observed in APL, but its prognostic significance remains unclear. We analyzed 245 newly diagnosed adult pa...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.3109/10428194.2013.842985

    authors: Poiré X,Moser BK,Gallagher RE,Laumann K,Bloomfield CD,Powell BL,Koval G,Gulati K,Holowka N,Larson RA,Tallman MS,Appelbaum FR,Sher D,Willman C,Paietta E,Stock W

    更新日期:2014-07-01 00:00:00

  • The insulin-like growth factor system in hematopoietic cells.

    abstract::The insulin-like growth factor (IGF) system regulates proliferation and differentiation of hematopoietic cells. IGFs exert their effects through specific receptors on growing and differentiating blood cells as they emerge from their small pool of ancestral stem cells. The IGF system is complex as both stimulating and ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.1080/10428190290011958

    authors: Zumkeller W

    更新日期:2002-03-01 00:00:00

  • Toxicology and pharmacokinetics of DT388IL3, a fusion toxin consisting of a truncated diphtheria toxin (DT388) linked to human interleukin 3 (IL3), in cynomolgus monkeys.

    abstract::The fusion toxin DT388IL3 composed of the catalytic and translocation domains of diphtheria toxin (DT388) linked to interleukin-3 (IL3) was administered to 6 cynomolgus monkeys which possessed cross-reactive IL3 receptors. Groups of 2 animals (1 male and 1 female) received up to 6 every other day slow intravenous infu...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190410001663572

    authors: Cohen KA,Liu TF,Cline JM,Wagner JD,Hall PD,Frankel AE

    更新日期:2004-08-01 00:00:00

  • Measurement of BCR-ABL1 transcripts on the International Scale in the United States: current status and best practices.

    abstract::Chronic myeloid leukemia (CML) results from the Philadelphia chromosome (Ph) translocation and expression of its fusion oncoprotein BCR-ABL1. BCR-ABL1 tyrosine kinase inhibitors (TKIs) are the standard therapy for Ph-positive CML. Achievement of deep molecular responses (typically defined as ≥4-log reduction in BCR-AB...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.1080/10428194.2016.1190974

    authors: Arora R,Press RD

    更新日期:2017-01-01 00:00:00

  • Surrogate end points for long-term outcomes in chronic myeloid leukemia.

    abstract::The natural history of the chronic phase (CP) of chronic myeloid leukemia (CML) and the high response rates achieved with BCR-ABL inhibitor therapy necessitate long-term evaluation of survival-based outcome measures. Prior to the availability of long-term BCR-ABL inhibitor data, short-term surrogate end points predict...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428194.2013.772607

    authors: Akwaa F,Liesveld J

    更新日期:2013-10-01 00:00:00

  • Improved outcome of human immunodeficiency virus-associated plasmablastic lymphoma of the oral cavity in the era of highly active antiretroviral therapy: a report of two cases.

    abstract::Plasmablastic lymphoma (PBL) is a recently described type of non-Hodgkin's lymphoma (NHL) that occurs in up to 3% of patients with HIV infection. Although the clinical-pathological features of several patients with HIV-associated plasmablastic lymphoma are documented, detailed description of clinical outcome is limite...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190410001697395

    authors: Lester R,Li C,Phillips P,Shenkier TN,Gascoyne RD,Galbraith PF,Vickars LM,Leitch HA

    更新日期:2004-09-01 00:00:00

  • Syndecan-1 (CD 138) in myeloma and lymphoid malignancies: a multifunctional regulator of cell behavior within the tumor microenvironment.

    abstract::Syndecan-1 is a transmembrane proteoglycan expressed on the surface of tumor cells of various origins including myeloma, Hodgkin's disease, and certain human immunodeficiency virus (HIV) associated lymphomas. Functional studies in myeloma reveal that syndecan-1 may act as a multifunctional regulator of cell behavior i...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428199909083378

    authors: Dhodapkar MV,Sanderson RD

    更新日期:1999-06-01 00:00:00

  • Fulminant bilateral cerebellar syndrome in a patient with chronic lymphocytic leukemia.

    abstract::A 55 year old patient with chronic lymphocytic leukemia (CLL) and long-standing excessive lymphocytosis developed a rapidly progressive neurological syndrome. Differential diagnosis focused on two rate neurological complications in this disease: direct brain infiltration by leukemic cells versus progressive multifocal...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199409049756

    authors: Quitt M,Bazac I,Gross B,Aghai E

    更新日期:1994-11-01 00:00:00

  • Correlation of bcl-2 with P-glycoprotein expression in chronic lymphocytic leukaemia and other haematological neoplasms but of neither marker with ex vivo chemosensitivity or patient survival.

    abstract::We compared bcl-2 with P-glycoprotein expression (C494 and JSB1), and both with ex vivo chemosensitivity by Differential Staining Cytotoxicity (DiSC) assay (25 cytotoxic drugs), in 76 fresh haematological specimens, including 51 chronic lymphocytic leukaemias (CLL). Strong correlations were seen between bcl-2 and Pgp ...

    journal_title:Leukemia & lymphoma

    pub_type: 临床试验,杂志文章

    doi:10.3109/10428199609045722

    authors: Bosanquet AG,Bell PB,Burlton AR,Amos TA

    更新日期:1996-12-01 00:00:00

  • The pathologic significance of the immunoglobulins expressed by chronic lymphocytic leukemia B-cells in the development of autoimmune hemolytic anemia.

    abstract::The increased number of CD5+ B-cells in some human autoimmune diseases, the frequent commitment of CD5+ B-cells to the production of natural autoantibodies, and the apparent involvement of these cells in the pathogenesis of the autoimmune hemolytic anemia (AIHA) in certain mouse models suggests a causal relationship b...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428199809092684

    authors: Efremov DG,Ivanovski M,Burrone OR

    更新日期:1998-01-01 00:00:00

  • Expanding Nilotinib Access in Clinical Trials (ENACT), an open-label multicenter study of oral nilotinib in adult patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase or blast crisis.

    abstract::Nilotinib has shown favorable safety in patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic (CML-CP) or accelerated phase (CML-AP) who failed prior imatinib, and superior efficacy over imatinib in newly diagnosed Ph+ patients with CML-CP. Reported here are the efficacy and sa...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,多中心研究

    doi:10.3109/10428194.2011.627480

    authors: Nicolini FE,Masszi T,Shen Z,Gallagher NJ,Jootar S,Powell BL,Dorlhiac-Llacer PE,Zheng M,Szczudlo T,Turkina A

    更新日期:2012-05-01 00:00:00

  • Significance of circulating plasma cells in multiple myeloma.

    abstract::The number of circulating plasma cells (CPC) was determined on mononuclear cell preparations after Giemsa (morphology) and light chain staining (immunocytochemistry). Both methods gave reproducible and identical results when CPC were 1% or more. Using this limit, no CPC were observed in MGUS (0/11) and primary amyloid...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199409049709

    authors: Zandecki M,Facon T,Preudhomme C,Canis F,Izydorczyk V,Lovi V,Hammad M,Bauters F,Cosson A

    更新日期:1994-08-01 00:00:00

  • Bronchiolitis obliterans organizing pneumonia in a patient with non-Hodgkin's lymphoma following R-CHOP and pegylated filgrastim.

    abstract::Bronchiolitis obliterans organizing pneumonia (BOOP) presents with fever, dyspnoea, pleuritic chest pain and hypoxia. The diagnosis can be made from radiological appearances on chest radiograph and CT scan correlated with histological findings following biopsy. We present a 52-year-old gentleman undergoing treatment f...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190500144615

    authors: Macartney C,Burke E,Elborn S,Magee N,Noone P,Gleadhill I,Allen D,Kettle P,Drake M

    更新日期:2005-10-01 00:00:00

  • Importance of [18F]fluorodeoxyglucose-positron emission tomography scanning for the monitoring of responses to immunotherapy in follicular lymphoma.

    abstract::We prospectively investigated the use of [18F]fluorodeoxyglucose (FDG)-positron emission tomography (PET) to kinetically monitor cell activation in six follicular lymphoma patients vaccinated with tumor lysate-pulsed autologous dendritic cells. PET revealed additional initial nodes suggestive of lymphoma, that were of...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190601094354

    authors: Baudard M,Comte F,Conge AM,Mariano-Goulart D,Klein B,Rossi JF

    更新日期:2007-02-01 00:00:00

  • Acquired C1 esterase inhibitor deficiency in lymphomas: prevalence, symptoms, and response to treatment.

    abstract::We retrospectively studied the prevalence of C1 esterase inhibitor (C1 INH) deficiency in 131 patients with various lymphomas. We determined C1 INH activity, C1 INH antigen, and C4 concentration at diagnosis and after chemotherapy. In follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL) and chronic lymphocy...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2015.1131273

    authors: Bekos C,Perkmann T,Krauth M,Raderer M,Lechner K,Jaeger U

    更新日期:2016-09-01 00:00:00